Related Experiment Video
Updated: Aug 13, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
Published on: February 10, 2023
Practical algorithms for pharmacologic management of the post myocardial infarction patient
James A Reiffel1, ,
1Cardiology Division, Department of Medicine, Columbia University, New York, New York, USA. jar2@columbia.edu
Insights
Post myocardial infarction (MI) pharmacologic management focuses on preventing future cardiac events and improving outcomes. Key therapies include ACE inhibitors, beta-blockers, and statins, guided by patient-specific risk factors.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Myocardial infarction (MI) management aims to prevent recurrent events and mitigate complications.
- Key goals include reducing mortality, reinfarction, and hospitalizations.
- Secondary objectives involve managing arrhythmias, left ventricular remodeling, and heart failure progression.
Purpose of the Study:
- To outline practical algorithms for post-MI pharmacologic management.
- To align treatment strategies with American Heart Association/American College of Cardiology guidelines.
- To tailor drug intensity based on left ventricular dysfunction, ischemia, and arrhythmia risk.
Main Methods:
- Review of current guidelines for post-MI pharmacologic therapy.
- Algorithm-based approach to drug selection and intensity.
- Consideration of patient-specific factors like LV ejection fraction, heart failure, diabetes, and contraindications.
Main Results:
- All post-MI patients require ACE inhibitors (or ARBs if intolerant) and antiplatelet therapy.
- Aldosterone blockade is recommended for specific patient groups with reduced LV function or diabetes.
- Beta-blockers are crucial for reducing mortality, especially in impaired LV function.
- Statins are recommended for patients with elevated cholesterol levels post-MI.
Conclusions:
- Pharmacologic management post-MI is multifaceted, targeting event prevention and secondary goals.
- Treatment intensity is individualized based on clinical parameters and risk stratification.
- Adherence to guideline-recommended therapies, including ACE inhibitors, beta-blockers, and statins, is essential for optimal patient outcomes.
Abstract:
The pharmacologic management of the patient post myocardial infarction (MI) aims to achieve several goals. Chief among these is to prevent subsequent events, which include death, reinfarction, and rehospitalization. Secondary goals include preventing arrhythmias, minimizing left ventricular (LV) remodeling, and preventing progression to heart failure. This review describes practical algorithms for use in the pharmacologic management of the patient post MI based on American Heart Association/American College of Cardiology guidelines. The intensity of drug treatment is determined guided by the degree of LV dysfunction and the presence or absence of ischemia and arrhythmic risk markers. All patients post MI require an angiotensin-converting enzyme (ACE) inhibitor and antiplatelet therapy, usually with aspirin. In individuals who cannot tolerate an ACE inhibitor, an angiotensin receptor blocker (ARB) is an adequate substitute. Numerous studies document the efficacy of ACE inhibitors, which decrease mortality and the risk of heart failure and stroke. Aldosterone blockade is recommended long-term for patients post MI with an LV ejection fraction < or = 40% and either symptomatic heart failure or diabetes. Use of a beta blocker is an important addition to most post-MI drug regimens. Beta blockers decrease mortality and are especially effective in patients with impaired LV function. Among the beta blockers, carvedilol, which also has alpha-adrenergic receptor blocking activity, was found to decrease mortality significantly in patients with low ejection fractions and heart failure. Another drug therapy of value in post-MI treatment is use of calcium-channel blockers. These are restricted to patients with conserved LV function in whom congestion is absent and in whom beta blockers are contraindicated. Current guidelines also recommend that patients post MI with elevated cholesterol levels should be prescribed lipid therapy with a statin at hospital discharge.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Cardiopulmonary Resuscitation IV: Pharmacological Management
Angina V: Nursing Management
Heart Failure V: Medical Management

